A CCP virus vaccine will likely move to phase two as soon as safety data comes in from phase one, Moderna CEO Stephane Bancel said on Tuesday. Moderna quickly developed an experimental vaccine against the CCP (Chinese Communist Party) virus, commonly known as novel coronavirus, delivering the first doses to federal researchers in February. The first doses were given to volunteers the next month. Things are going well with the trial and Bancel expects to move to phase two as soon as safety data comes in from phase one, Bancel said during an appearance on CNBC’s “Squawk Box” on April...